HLS Therapeutics Inc.
HLTRF
$3.36
-$0.07-1.98%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 15.20M | 13.51M | 14.17M | 12.62M | 15.54M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 15.20M | 13.51M | 14.17M | 12.62M | 15.54M |
| Cost of Revenue | 4.28M | 3.81M | 3.87M | 3.83M | 4.22M |
| Gross Profit | 10.92M | 9.70M | 10.30M | 8.79M | 11.32M |
| SG&A Expenses | 5.22M | 5.57M | 5.60M | 5.62M | 6.18M |
| Depreciation & Amortization | 5.46M | 5.51M | 5.48M | 5.36M | 5.43M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.96M | 14.89M | 14.95M | 14.81M | 15.84M |
| Operating Income | 237.00K | -1.37M | -778.00K | -2.19M | -300.00K |
| Income Before Tax | -1.98M | -3.94M | -2.50M | -4.46M | -2.94M |
| Income Tax Expenses | -647.00K | -17.00K | 242.00K | -23.00K | 85.00K |
| Earnings from Continuing Operations | -1.34M | -3.92M | -2.74M | -4.44M | -3.02M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.34M | -3.92M | -2.74M | -4.44M | -3.02M |
| EBIT | 237.00K | -1.37M | -778.00K | -2.19M | -300.00K |
| EBITDA | 5.18M | 4.14M | 4.71M | 3.17M | 4.66M |
| EPS Basic | -0.04 | -0.12 | -0.09 | -0.14 | -0.10 |
| Normalized Basic EPS | -0.04 | -0.08 | -0.05 | -0.09 | -0.06 |
| EPS Diluted | -0.04 | -0.12 | -0.09 | -0.14 | -0.11 |
| Normalized Diluted EPS | -0.04 | -0.08 | -0.05 | -0.09 | -0.06 |
| Average Basic Shares Outstanding | 33.38M | 31.40M | 31.64M | 31.79M | 30.23M |
| Average Diluted Shares Outstanding | 33.38M | 31.40M | 31.64M | 31.79M | 30.23M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |